<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547910</url>
  </required_header>
  <id_info>
    <org_study_id>ChildrensMHIPoland</org_study_id>
    <nct_id>NCT01547910</nct_id>
  </id_info>
  <brief_title>Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children</brief_title>
  <official_title>Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children - a Randomized, Double Blind, Placebo Controlled, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piotr Socha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pediatric Municipal Hospital of Rzeszow, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Memorial Health Institute, Poland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate efficacy of fish oil (EPA/DHA) in children with
      non-alcoholic fatty liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      76 children or adolescents aged 6-19 with NAFLD will be included in the study. Diagnosis of
      NAFLD is set by increased alanine transaminase and features of liver steatosis on ultrasound.
      Patients will be randomized to receive either fish oil (EPA/DHA, 400-1200mg) or placebo
      (sunflower oil) for 6 months. All children will be advised to reduce weight (dietetic
      intervention + increased physical activity). Laboratory tests, liver ultrasound,
      anthropometric analysis will be performed at the start, after 3 months and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum alanine transaminase level decrease min. 0.3 upper limit of normal</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients in whom ALT decreased min. 0.,3 ULN in 'fish oil' group compared to 'placebo' group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>normalization of liver imaging on ultrasound</measure>
    <time_frame>after 6 months of therapy</time_frame>
    <description>'Fish oil' group will be compared to 'placebo' group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT and AST activity</measure>
    <time_frame>6 months</time_frame>
    <description>'Fish oil' group will be compared to 'placebo' group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance markers as Homa-IR</measure>
    <time_frame>6 months</time_frame>
    <description>'Fish oil' group will be compared to 'placebo' group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat and lean body mass measurements</measure>
    <time_frame>6 months</time_frame>
    <description>'Fish oil' group will be compared to 'placebo' group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caloric intake including fat intake and sucrose intake</measure>
    <time_frame>6 months</time_frame>
    <description>'Fish oil' group will be compared to 'placebo' group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children will receive fish oil capsules according to age as described in the protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sunflower oil in the same capsules (the same shape and colour) given in the same regime as 'fish oil' capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Fish oil given in supplementary dose</description>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 6-19

          -  overweight or obesity

          -  ALT activity over 130% of upper limit norm

          -  hyperechogenicity of the liver on ultrasound

        Exclusion Criteria:

          -  HCV, HBV infection

          -  cholestasis

          -  chronic/acute liver failure

          -  alpha-1-antitrypsin deficiency

          -  Wilson disease

          -  type 2 diabetes mellitus

          -  beta-oxidation defects

          -  alcohol consumption

          -  history of parenteral nutrition

          -  use of drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Socha</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Memorial Health Institute, Warsaw, Poland</affiliation>
  </overall_official>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Memorial Health Institute, Poland</investigator_affiliation>
    <investigator_full_name>Piotr Socha</investigator_full_name>
    <investigator_title>Professor PhD MD, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>fatty liver</keyword>
  <keyword>hepatitis</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>unsaturated fatty acids</keyword>
  <keyword>NAFLD, children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

